ROIVANT SCIENCES LTD. (ROIV) Spending and interest coverage
- R&D / revenue · 12 months: Value 9704.05%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4611.38%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 9704.05% | Research and development expense / revenue. Period ending 2026-06-30. $730.91M ÷ $7.53M × 100 ≈ 9704.05% |
| Stock-based compensation / revenue · 12 months | 4611.38% | Share-based compensation / revenue. Period ending 2026-06-30. $347.33M ÷ $7.53M × 100 ≈ 4611.38% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 730.91M USD | Research and Development Expense |
| Revenue | 7.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 347.33M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -596.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $730.91M | $7.53M | $347.33M | $-596.14M | (m) | 9704.05% | 4611.38% | (m) | (m) |
| 2026-03-31 | $681.81M | $8.26M | $346.17M | $-515.07M | (m) | 8254.38% | 4190.86% | (m) | (m) |
| 2025-12-31 | $628.11M | $13.31M | $352.48M | $-1.22B | (m) | 4719.05% | 2648.26% | (m) | (m) |
| 2025-09-30 | $604.32M | $20.33M | $331.17M | $-1.15B | (m) | 2972.70% | 1629.04% | (m) | (m) |
| 2025-06-30 | $582.83M | $23.23M | $321.02M | $-1.19B | (m) | 2508.61% | 1381.72% | (m) | (m) |
| 2025-03-31 | $550.41M | $29.05M | $289.03M | $-1.00B | (m) | 1894.51% | 994.83% | (m) | (m) |
| 2024-12-31 | $574.56M | $122.58M | $252.26M | $-1.18B | (m) | 468.70% | 205.79% | (m) | (m) |
| 2024-09-30 | $541.11M | $129.13M | $222.91M | $4.22B | (m) | 419.05% | 172.63% | (m) | (m) |
| 2024-06-30 | $509.81M | $158.30M | $200.56M | $4.40B | $39.27M | 322.05% | 126.69% | 112.01× | Reported |
| 2024-03-31 | $501.74M | $124.80M | $199.63M | $4.24B | $34.78M | 402.05% | 159.96% | 121.97× | Reported |
| 2023-12-31 | $512.69M | $123.24M | $178.18M | $4.27B | $36.18M | 416.01% | 144.58% | 118.13× | Reported |
| 2023-09-30 | $514.51M | $103.15M | $181.59M | $-1.17B | $35.18M | 498.78% | 176.04% | -33.12× | Reported |
| 2023-06-30 | $514.52M | $78.58M | $194.25M | $-1.17B | $34.27M | 654.73% | 247.18% | -34.13× | Reported |
| 2023-03-31 | $525.22M | $61.28M | $217.78M | $-1.18B | $27.97M | 857.07% | 355.39% | -42.02× | Reported |
| 2022-12-31 | $528.43M | $43.13M | $269.66M | $-1.21B | (m) | 1225.30% | 625.28% | (m) | (m) |
| 2022-09-30 | $540.25M | $50.42M | $283.15M | $-1.08B | (m) | 1071.58% | 561.62% | (m) | (m) |
| 2022-06-30 | $540.35M | $51.87M | $618.48M | $-1.48B | $7.14M | 1041.74% | 1192.37% | -207.22× | Reported |
| 2022-03-31 | $483.04M | $55.29M | $564.96M | $-1.35B | $7.04M | 873.70% | 1021.88% | -191.97× | Reported |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $236.63M | $23.80M | $84.96M | $-1.07B | $2.81M | 994.44% | 357.04% | -381.24× | Reported |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |